Recombinant human bone morphogenetic proteins (rhBMPs) have been extensively investigated for developing therapeutic strategies aimed at the restoration and treatment of orthopaedic as well as craniofacial conditions. In this first part of the review, we discuss the rationale for the necessary use of carrier systems to deliver rhBMP-2 and rhBMP-7 to sites of bone tissue regeneration and repair. General requirements for growth factor delivery systems emphasizing the distinction between localized and release-controlled delivery strategies are presented highlighting the current limitations in the development of an effective rhBMP delivery system applicable in clinical bone tissue engineering.
Bibliographical noteFunding Information:
Acknowledgments The authors wish to thank grants from the Shriners of North America, Fonds de la Recherche en Santé du Québec, the National Science and Engineering Research Council, the Canadian Institutes of Health Research (CIHR)— Regenerative Medicine/Nanomedicine and the Center for Bio-recognition and Biosensors (CBB), McGill University, Montréal, Québec, Canada. Dr. Haidar acknowledges scholarships from the Center for Bone and Periodontal Diseases Research and the Shriners Hospital, Montréal, Québec, Canada.
- Bone morphogenetic proteins
- Bone regeneration
- Bone repair
- Craniofacial surgery
- Delivery systems